Antagonism of N-methyl-D-aspartate-induced transmitter release in the rat striatum by phencyclidine-like drugs and its relationship to turning behavior.
L. Snell, K. Johnson
Journal of Pharmacology and Experimental Therapeutics October 1, 1985 DOI: 10.1016/s0022-3565(25)23841-1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Laboratory study Peer reviewed |
|---|---|
| Population | Rat striatal tissue and rats with unilateral destruction of the substantia nigra |
| Interventions | Phencyclidine Etoxadrol (-)-Cyclazocine Ketamine Ethylketocyclazocine Morphine Dexoxadrol m-amino-PCP Levoxadrol m-nitro-PCP (+)-Cyclazocine |
| Dose | 10 mg/kg (dexoxadrol, m-amino-PCP, (-)-cyclazocine, levoxadrol, m-nitro-PCP, (+)-cyclazocine); 100 nM (dexoxadrol, m-amino-PCP, (-)-cyclazocine and their enantiomers/analog); 30,000 nM (morphine) |
| Measures | IC50 for inhibition of NMDA-stimulated acetylcholine efflux, ipsilateral turning |
| Key points | PCP-like drugs inhibited NMDA-stimulated acetylcholine efflux in rat striatum with differing potencies (PCP IC50 68 nM; ketamine 1600 nM), and several also induced ipsilateral turning in rats with unilateral substantia nigra lesions. The authors conclude, based on their prior work on these drugs' dopaminergic properties, that the turning results from nondopaminergic properties rather than dopaminergic ones. |
Abstract
Representatives from several chemical classes known to share behavioral properties with phencyclidine [(1-phenylcyclohexyl)piperidine] (PCP) have been shown to antagonize the excitatory effects of N-methylaspartate on spinal neurons selectively. This study compared the abilities of several of these PCP-like drugs to inhibit N-methyl-D-aspartate (NMDA)-stimulated efflux of acetylcholine in rat striatum. PCP completely inhibited this parameter with an IC50 value of 68 nM. The IC50 values (nanomolar) found for the other drugs tested were as follows: etoxadrol (98), (-)-cyclazocine (120), N-allylnormetazocine (or SKF 10047) (940), ketamine (1600) and ethylketocyclazocine (8300). Morphine had no effect at concentrations as high as 30,000 nM. In addition, 100 nM dexoxadrol, 1-[1-(napthyl)cyclohexyl]piperidine HCl (m-amino PCP) and (-)-cyclazocine inhibited NMDA-induced acetylcholine release by about 50%, whereas the same concentration of their enantiomers (or a structural analog in the case of m-amino-PCP) produced no significant effect. It was also found that 10 mg/kg of dexoxadrol, m-amino-PCP and (-)-cyclazocine induced significant ipsilateral turning in rats with unilateral destruction of the substantia nigra, whereas 10 mg/kg of levoxadrol, 1-[1-(m-nitrophenyl)cyclohexyl]piperidine HCL (m-nitro-PCP) and (+)-cyclazocine produced no such similar effect. In spite of the ability of several dopaminergic antagonists to block turning produced by (+/-)-cyclazocine, we concluded, based on our previously reported studies of the dopaminergic properties of these drugs, that turning is the result of nondopaminergic properties of the PCP-like drugs.(ABSTRACT TRUNCATED AT 250 WORDS)
Citations in the library
Cited by 11
- R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder. Pharmacology, Biochemistry, and Behavior April 22, 2020
- Contrasting Neurochemical Interactions of Tiletamine, a Potent Phencyclidine (PCP) Receptor Ligand, with the N ‐Methyl‐D‐Aspartate‐Coupled and ‐Uncoupled PCP Recognition Sites Journal of Neurochemistry March 1, 1991
- Allosteric inhibition of NMDA receptors by low dose ketamine. Molecular Psychiatry March 1, 2025
- Ketamine and phencyclidine: the good, the bad and the unexpected. British Journal of Pharmacology September 2015
- The role of striatal dopaminergic mechanisms in rotational behavior induced by phencyclidine and phencyclidine-like drugs. Psychopharmacology 1998
and 6 more in the library